Repros Therapeutics (RPRX -1%) says the FDA has scheduled a meeting to discuss the Phase 2 tests for its low dose oral Proellex treatment for endometriosis. The teleconference will be held during the last week of August.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs